Subcutaneous rituximab noninferior to IV formulation in follicular lymphoma Healio Subcutaneous rituximab appeared noninferior to the IV formulation in patients with follicular lymphoma, conferring similar outcomes without increased safety issues, according to preliminary study results. The SABRINA study — a two-stage, randomized, ... |
